AR039219A1 - Compuestos imidazo-sustituidos - Google Patents
Compuestos imidazo-sustituidosInfo
- Publication number
- AR039219A1 AR039219A1 ARP030101141A ARP030101141A AR039219A1 AR 039219 A1 AR039219 A1 AR 039219A1 AR P030101141 A ARP030101141 A AR P030101141A AR P030101141 A ARP030101141 A AR P030101141A AR 039219 A1 AR039219 A1 AR 039219A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- bond
- alkyl
- atoms
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000003107 substituted aryl group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 201000004193 respiratory failure Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos correspondientes a la fórmula (1), así como también formulaciones farmacéuticas, métodos de preparación y usos de los mismos para el tratamiento de enfermedades mediadas por p38. Reivindicación1: Un compuesto representado por la fórmula 1 caracterizado porque Z es N o CH, Z1 es seleccionado entre N y CH cuando el enlace entre los átomos C5 y Z1 es un enlace simple, y Z1 es C cuando el enlace entre C5 y Z1 es un enlace doble; R1 es H o alquilo; R2 es alquilo, hidroxialquilo, aralquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heteroalquilo, heterociclilo opcionalmente sustituido, arilo opcionalmente sustituido, o heteroarilo opcionalmente sustituido; A está ausente o es -O-, -S(O)n-, -CHR´-, -C(=O)- o -NR3- en donde n es 0,1, o 2, R´ es H o alquilo y R3 es H, alquilo, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o cicloalquilo opcionalmente sustituido; el enlace entre los átomos C5 y Z1 es un enlace simple o doble; el enlace entre los átomos C8 y C9 es un enlace simple o doble; e Y es un alquilo, heteroalquilo, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; o isómeros, sales farmacéuticamente aceptables, ésteres o prodrogas del mismo. Reivindicación 29: El uso de acuerdo con la reivindicación 28, caracterizado porque el trastorno mediado por p38 es seleccionado entre el grupo que consiste en artritis, enfermedad de Crohn, enfermedad de Alzheimer, síndrome del colon irritable, síndrome de la insuficiencia respiratoria del adulto y enfermedad pulmonar obstructiva crónica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36992902P | 2002-04-03 | 2002-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039219A1 true AR039219A1 (es) | 2005-02-09 |
Family
ID=28675587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101141A AR039219A1 (es) | 2002-04-03 | 2003-04-02 | Compuestos imidazo-sustituidos |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US6949560B2 (es) |
| EP (1) | EP1492790A1 (es) |
| JP (1) | JP2006503802A (es) |
| KR (1) | KR100656205B1 (es) |
| CN (1) | CN1293078C (es) |
| AR (1) | AR039219A1 (es) |
| AU (1) | AU2003215675B2 (es) |
| BR (1) | BR0308937A (es) |
| CA (1) | CA2479644A1 (es) |
| MX (1) | MXPA04009585A (es) |
| PL (1) | PL374544A1 (es) |
| RU (1) | RU2310657C2 (es) |
| WO (1) | WO2003082871A1 (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050070554A1 (en) * | 2003-08-27 | 2005-03-31 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| DE10361659A1 (de) | 2003-12-30 | 2005-07-28 | Osram Opto Semiconductors Gmbh | Verfahrem zum Herstellen einer epitaktischen Bauelementschichtenfolge und optoelektronischer Halbleiterchip |
| FR2873118B1 (fr) * | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| JP2010522155A (ja) * | 2007-03-20 | 2010-07-01 | カディラ ファーマシューティカルズ リミテッド | Ｐ３８阻害剤 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| CN103957910A (zh) * | 2011-10-21 | 2014-07-30 | 葛兰素史克有限责任公司 | 增加先天免疫反应的化合物和方法 |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| JP6449244B2 (ja) | 2013-04-19 | 2019-01-09 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｆｇｆｒ抑制剤としての二環式複素環 |
| CN105481858B (zh) * | 2014-10-11 | 2019-05-17 | 上海医药集团股份有限公司 | 一种含氮稠杂环化合物、其制备方法、组合物及应用 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| CA3003433A1 (en) | 2015-10-27 | 2017-05-04 | Children's Hospital Medical Center | Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| WO2018004258A1 (ko) * | 2016-06-28 | 2018-01-04 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
| KR20180002053A (ko) | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
| WO2018090939A1 (zh) * | 2016-11-16 | 2018-05-24 | 上海瑛派药业有限公司 | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 |
| EP3587419A4 (en) * | 2017-02-27 | 2020-08-05 | Betta Pharmaceuticals Co., Ltd. | FGFR INHIBITOR AND APPLICATION OF IT |
| US11091485B2 (en) | 2017-05-23 | 2021-08-17 | Shengke Pharmaceuticals (Jiangsu) Ltd. | Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3691620B1 (en) | 2017-10-05 | 2022-07-27 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| US11267815B2 (en) | 2017-10-30 | 2022-03-08 | Shanghai Ringene Biopharma Co., Ltd. | Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof |
| WO2019085894A1 (zh) * | 2017-10-30 | 2019-05-09 | 如东凌达生物医药科技有限公司 | 一类含氮稠环化合物及其制备方法和用途 |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| CN119241541A (zh) | 2018-05-04 | 2025-01-03 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
| CN110857300B (zh) * | 2018-08-23 | 2021-11-05 | 上海凌达生物医药有限公司 | 一类稠环三氮唑类化合物、制备方法和用途 |
| TW202024084A (zh) * | 2018-08-27 | 2020-07-01 | 大陸商貝達藥業股份有限公司 | 新型氮雜三環類化合物的鹽型、晶型及其用途 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| CN113646314B (zh) * | 2019-03-08 | 2023-12-08 | 首药控股(北京)股份有限公司 | Fgfr4激酶抑制剂及其制备方法和用途 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| BR112022002698A2 (pt) | 2019-08-14 | 2022-07-19 | Incyte Corp | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022006977A2 (pt) | 2019-10-11 | 2022-09-20 | Incyte Corp | Aminas bicíclicas como inibidores de cdk2 |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL293001A (en) | 2019-12-04 | 2022-07-01 | Incyte Corp | Derivatives of fgfr repressors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2022032071A1 (en) * | 2020-08-07 | 2022-02-10 | Abm Therapeutics Corporation | Kinase inhibitors and uses thereof |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522947A (en) * | 1982-03-29 | 1985-06-11 | Usv Pharmaceutical Corporation | Certain 1,3-oxazolo[4,5H]quinolines useful as anti-allergy agents |
| US4656281A (en) * | 1983-03-18 | 1987-04-07 | Usv Pharmaceutical Corp. | Imidazo quinoline compounds useful as anti-allergy agents |
| DE3502689A1 (de) * | 1985-01-26 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Elektrophotographisches aufzeichnungsmaterial |
| US4831040A (en) * | 1988-02-01 | 1989-05-16 | Rorer Pharmaceutical Corporation | Method of prevention and treatment of peptic ulcers |
| GB9123916D0 (en) | 1991-11-11 | 1992-01-02 | Wellcome Found | Heterocyclic compounds |
| DE19510965A1 (de) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung |
| JPH11292878A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | イミダゾナフチリジン誘導体 |
| AU776250B2 (en) * | 1999-10-21 | 2004-09-02 | F. Hoffmann-La Roche Ag | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase |
| EP1315726A1 (en) * | 2000-08-31 | 2003-06-04 | F. Hoffmann-La Roche Ag | 7- oxo pyridopyrimidines as inhibitors of cellular proliferation |
| DE60206363T2 (de) | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
-
2003
- 2003-03-27 JP JP2003580336A patent/JP2006503802A/ja active Pending
- 2003-03-27 KR KR1020047015609A patent/KR100656205B1/ko not_active Expired - Fee Related
- 2003-03-27 EP EP03745276A patent/EP1492790A1/en not_active Withdrawn
- 2003-03-27 CA CA002479644A patent/CA2479644A1/en not_active Abandoned
- 2003-03-27 CN CNB038075369A patent/CN1293078C/zh not_active Expired - Fee Related
- 2003-03-27 AU AU2003215675A patent/AU2003215675B2/en not_active Ceased
- 2003-03-27 BR BR0308937-1A patent/BR0308937A/pt not_active IP Right Cessation
- 2003-03-27 PL PL03374544A patent/PL374544A1/xx not_active Application Discontinuation
- 2003-03-27 RU RU2004132204/04A patent/RU2310657C2/ru active
- 2003-03-27 MX MXPA04009585A patent/MXPA04009585A/es active IP Right Grant
- 2003-03-27 WO PCT/EP2003/003178 patent/WO2003082871A1/en not_active Ceased
- 2003-04-02 AR ARP030101141A patent/AR039219A1/es unknown
- 2003-04-03 US US10/406,364 patent/US6949560B2/en not_active Expired - Fee Related
-
2005
- 2005-05-04 US US11/122,137 patent/US7081462B2/en not_active Expired - Fee Related
-
2006
- 2006-07-13 US US11/486,348 patent/US7285561B2/en not_active Expired - Fee Related
- 2006-07-13 US US11/486,193 patent/US7285559B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003215675B2 (en) | 2007-07-12 |
| US7285561B2 (en) | 2007-10-23 |
| WO2003082871A1 (en) | 2003-10-09 |
| US7081462B2 (en) | 2006-07-25 |
| CA2479644A1 (en) | 2003-10-09 |
| KR20040099384A (ko) | 2004-11-26 |
| MXPA04009585A (es) | 2005-01-11 |
| EP1492790A1 (en) | 2005-01-05 |
| US20060252783A1 (en) | 2006-11-09 |
| US20030232847A1 (en) | 2003-12-18 |
| AU2003215675A1 (en) | 2003-10-13 |
| US6949560B2 (en) | 2005-09-27 |
| US20060252784A1 (en) | 2006-11-09 |
| KR100656205B1 (ko) | 2006-12-12 |
| US7285559B2 (en) | 2007-10-23 |
| CN1293078C (zh) | 2007-01-03 |
| BR0308937A (pt) | 2005-01-04 |
| CN1646529A (zh) | 2005-07-27 |
| US20050197352A1 (en) | 2005-09-08 |
| PL374544A1 (en) | 2005-10-31 |
| RU2004132204A (ru) | 2005-11-20 |
| RU2310657C2 (ru) | 2007-11-20 |
| JP2006503802A (ja) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039219A1 (es) | Compuestos imidazo-sustituidos | |
| MX2022005399A (es) | Compuestos. | |
| AR047976A1 (es) | Compuestos inmunosupresores y composiciones | |
| UY31084A1 (es) | Compuestos de azaindol para la inhibicion de b-secretasa | |
| UY31083A1 (es) | Derivados de sulfoximinas para la inhibicion de b-secretasa | |
| UY29927A1 (es) | Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones | |
| UY30408A1 (es) | Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| BRPI0518651A2 (pt) | composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| UY28578A1 (es) | Derivados de amida | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| BR0112475A (pt) | N-óxidos como pró-drogas antagonistas de receptor de nk1 de derivados 4-fenil-piridina | |
| GT200400174A (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5 ht4 | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| NO20081128L (no) | 4-fenyl-6-substituerte-pyrimidin-2-karbonitrilderivater | |
| ATE440834T1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| AR064657A1 (es) | 8- alquinilxantinas y derivados | |
| CL2004000769A1 (es) | Compuestos derivados del acido [2-(8,9-dioxo-2,6-diazabiciclo [5,2,o]non-1-(7)-en-2-il) alquil]fosfonico, antagonistas del receptor n-metil-d-aspartato (nmda); procedimiento de preparacion; composicion farmaceutica; y su uso para tratar desordenes va | |
| CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
| MY207696A (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |